Sale of drugs online: Panel for setting up of national portal

Image
Press Trust of India New Delhi
Last Updated : Nov 11 2016 | 8:42 PM IST
A sub-committee tasked to evaluate the feasibility of online sale of drugs has recommended setting up of a national portal for registration of e-pharmacies to ensure that only registered sellers sell it on e-prescription generated by registered medical practitioners.
Its recommendations have come in the context of the current guidelines of the Drugs and Cosmetics Act and Rules, and have been submitted to the Central Drugs Standard Control Organisation (CDSCO).
The recommendations of the committee, which was formed last year by Drug Controller General of India (DGCI), will now be forwarded to the Union Ministry of Health.
The sub-committee, under the chairmanship of Maharashtra Food and Drug Administration (FDA) Commissioner Harshadeep Kamble, has suggested that medicines should be allowed to be sold online in phased manner after establishing sufficient checks and balances.
"In the absence of regulation and registration of e-pharmacies, people can be cheated by clandestine unauthourised operators which can lead to consumption of spurious drugs based on self medication.
"Also, there is abuse of medicines through e-pharmacies. People indulge in self-medication,end up taking wrong drugs and there antibiotics misuse. Thus, it can lead to commercial and health exploitation of public at large," said an official of the DGCI.
At present, the online sale of prescriptions drugs (those falling under schedule H, H1, G and X) is illegal. However, for non-prescription drugs, those having the licences can sell them which are without prescription even on online.
On December 30, last year, the DCGI had instructed drug control officers of all states to take action against those indulging in online sale of drugs in the interest of public health.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 11 2016 | 8:42 PM IST

Next Story